News for Hyloris Pharmaceuticals SA (HYL.BR)

PR NewswireTEL AVIV, Israel and RALEIGH, N.C., April 10, 2025 Revenue-generating with an exciting, diversified, largely externally funded, advanced develop

PR NewswireTEL AVIV, Israel and RALEIGH, N.C., Feb. 25, 2025 - Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone pay

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted to €4.4 millionStronger growth expected in 2024 of both sales and gross margin, mainly...

Communication at the request of the FSMA on the transactions with Qliniq Revision of 2022 and half-year of 2023 financial statements following a correction of a non-cash error in the...

Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty bio...

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Maxigesic® IV, a Potent Non-opioid Painkiller, Marketed in the U.S. under the Tradename Combogesic® IVMaxigesic® IV...

Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus Equal Partnership with AFT Pharmaceuticals for Development of a Drug Releasing Mucoadhesive Film for VLS Limited...

Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia PTX-252 is a novel molecular entity developed in collaboration with Pleco Therapeutics Liège,...

Valacyclovir is an Antiviral Medication that is Commonly Used to Treat Infections Caused by Herpes Viruses Clinical Study Demonstrates Comparable Relative Bioavailability to Valaciclovir Tablets under...

Territorial expansion for a product candidate previously exclusively targeting the U.S.Kye Pharmaceuticals to register and commercialize in Canada Liège, Belgium – 24 October 2023 – 7AM CET –...

IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF...

Maxigesic® IV, a potent non-opioid painkiller, to be marketed in the U.S. under the tradename Combogesic® IVFirst U.S. sales expected in early 2024, triggering a milestone payment of USD 2,1 million Liège,